How Fatty Liver Disease Works—and Why It's So Common

A Silent Epidemic in Plain Sight

It produces no pain, no jaundice, no obvious warning signs — yet metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver condition on the planet. Estimates from recent research put the global prevalence at roughly 30% of all adults, with projections suggesting that figure could surpass 55% by 2040 as obesity and diabetes rates continue to climb. Understanding how MASLD develops — and why it so often goes undetected — is essential for anyone trying to protect their long-term health.

What Is MASLD?

MASLD — until recently called non-alcoholic fatty liver disease (NAFLD) — occurs when excess fat accumulates in liver cells in people who drink little or no alcohol. The name was updated in 2023 by major liver disease societies to better reflect the underlying metabolic drivers of the condition. To be diagnosed with MASLD, a person must have confirmed fat in the liver (hepatic steatosis) plus at least one metabolic risk factor, such as obesity, type 2 diabetes, high blood pressure, or abnormal cholesterol levels.

The condition exists on a spectrum. At one end sits simple steatosis — fat accumulation without significant inflammation. Further along is metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), where inflammation and liver cell damage appear. Left unchecked, MASH can progress to fibrosis (scarring), cirrhosis (extensive scarring that disrupts liver function), and ultimately liver failure or hepatocellular carcinoma (liver cancer).

How Fat Accumulates in the Liver

The liver plays a central role in fat metabolism — it processes fatty acids arriving from the digestive system and fat tissue, packages them for distribution around the body, or burns them for energy. MASLD develops when this system is thrown off balance, primarily through insulin resistance.

When cells stop responding properly to insulin, the pancreas pumps out more of it. High insulin levels signal fat cells to release fatty acids into the bloodstream, and the liver absorbs far more than it can process. At the same time, the liver ramps up its own fat production — a process called de novo lipogenesis. The result: fat droplets build up inside liver cells.

A deeper problem lies in the mitochondria, the energy-generating machinery inside cells. In MASLD, mitochondrial function deteriorates, impairing the liver's ability to burn fats. This dysfunction also increases oxidative stress — a buildup of damaging molecules that triggers inflammation and cell death, accelerating the transition from simple fatty liver to MASH.

Diet also plays a direct role. High consumption of fructose (found in sugary drinks and ultra-processed foods) and excess omega-6 fatty acids have been linked to faster disease progression, as fructose is almost exclusively metabolized in the liver and can overwhelm its capacity.

Who Is Most at Risk?

• People with obesity, especially excess abdominal fat
• Type 2 diabetics — up to 70% may have MASLD
• People with metabolic syndrome (high blood pressure, high triglycerides, low HDL cholesterol)
• Those eating high-fructose, high-calorie diets
• Older adults, in whom metabolic efficiency naturally declines

MASLD is also increasingly diagnosed in children and adolescents, affecting an estimated 7–14% of young people globally — a trend closely tied to rising childhood obesity rates.

Why It Often Goes Unnoticed

MASLD is frequently called a "silent" disease because most people experience no symptoms in the early stages. If symptoms do appear, they tend to be vague: fatigue, mild abdominal discomfort, or a general sense of weakness. The condition is often discovered incidentally — through abnormal liver enzyme results on a routine blood test, or during an ultrasound performed for another reason.

This silence is dangerous. Each stage of fibrosis takes an average of seven years to progress, meaning serious liver damage can accumulate over decades without a person ever feeling ill.

Diagnosis and Treatment

Doctors diagnose MASLD using imaging (ultrasound, MRI, or CT scan) to detect fat in the liver, combined with blood tests and clinical assessment of metabolic risk factors. Non-invasive scoring tools like the FIB-4 index help estimate the degree of fibrosis without a liver biopsy.

The cornerstone of treatment remains lifestyle change: a healthy diet, regular physical activity, and weight loss. Even a 5–10% reduction in body weight can significantly reduce liver fat and inflammation. On the pharmacological front, GLP-1 receptor agonists — the same class of drugs as semaglutide (Ozempic) — have shown promising results. Semaglutide received FDA approval in 2025 specifically for treating adults with MASH and moderate-to-advanced fibrosis, marking a milestone in the field.

Beyond the liver itself, cardiovascular disease remains the leading cause of death among MASLD patients — a reminder that this condition is as much a heart disease risk as a liver one.

The Bottom Line

MASLD is not an inevitable consequence of modern life, but it is a predictable one when metabolic health is neglected. Because it progresses silently over years, awareness and early screening are critical — especially for anyone carrying metabolic risk factors. The liver is remarkably resilient in early stages; intervening before fibrosis sets in can reverse the damage entirely.